ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Accounts Payable
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Accounts Payable of $266.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2019-11-06
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for the quarter ending 2019-09-30 was $3.91M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for the quarter ending 2019-06-30 was -$3.49M, a 229.71% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for the quarter ending 2019-03-31 was -$151.00K.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for the quarter ending 2018-12-31 was $3.96M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for fiscal 2018 was $3.37M, a 2.52% decline from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for fiscal 2017 was $3.46M, a 38.25% increase from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for fiscal 2016 was $2.50M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts payable for fiscal 2015 was -$1.98M, a 162.39% decline from fiscal 2014.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 47 month |
|---|---|---|---|---|---|
| 2019-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $417.00K derived: sum of 2 quarters · filed 2019-11-06 | $266.00K 10-Q · filed 2019-11-06 | $4.23M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-06-30 | -$3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$3.64M 10-Q · filed 2019-08-02 | $321.00K derived: sum of 3 quarters · filed 2019-08-02 | -$1.65M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-03-31 | -$151.00K 10-Q · filed 2019-05-07 | $3.81M derived: sum of 2 quarters · filed 2019-05-07 | $1.84M derived: sum of 3 quarters · filed 2019-11-06 | $4.54M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $2.00M derived: sum of 2 quarters · filed 2019-11-06 | $4.69M derived: sum of 3 quarters · filed 2019-11-06 | $3.37M 10-K · filed 2019-02-20 | |
| 2018-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $724.00K derived: sum of 2 quarters · filed 2019-11-06 | -$593.00K 10-Q · filed 2019-11-06 | -$1.01M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $1.38M 10-Q · filed 2019-08-02 | $956.00K derived: sum of 3 quarters · filed 2019-08-02 | -$1.52M derived: sum of 4 quarters · filed 2019-08-02 | |
| 2018-03-31 | -$1.32M 10-Q · filed 2019-05-07 | -$1.74M derived: sum of 2 quarters · filed 2019-05-07 | -$4.21M derived: sum of 3 quarters · filed 2019-05-07 | -$847.00K derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | -$420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$2.89M derived: sum of 2 quarters · filed 2019-02-20 | $470.00K derived: sum of 3 quarters · filed 2019-02-20 | $3.46M 10-K · filed 2019-02-20 | |
| 2017-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $890.00K derived: sum of 2 quarters · filed 2018-11-06 | $3.88M 10-Q · filed 2018-11-06 | $2.54M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $6.35M 10-Q · filed 2018-08-03 | $5.01M derived: sum of 3 quarters · filed 2019-02-20 | $6.03M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-03-31 | $2.99M 10-Q · filed 2018-05-08 | $1.65M derived: sum of 2 quarters · filed 2019-02-20 | $2.67M derived: sum of 3 quarters · filed 2019-02-20 | $2.85M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2016-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$323.00K derived: sum of 2 quarters · filed 2019-02-20 | -$136.00K derived: sum of 3 quarters · filed 2019-02-20 | $2.50M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $1.20M derived: sum of 2 quarters · filed 2017-11-03 | $3.84M 10-Q · filed 2017-11-03 | $2.40M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $2.83M 10-Q · filed 2017-07-28 | $1.39M derived: sum of 3 quarters · filed 2018-02-21 | -$3.93M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | $2.64M 10-Q · filed 2017-05-05 | $1.20M derived: sum of 2 quarters · filed 2018-02-21 | -$4.12M derived: sum of 3 quarters · filed 2018-02-21 | $219.00K derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$6.76M derived: sum of 2 quarters · filed 2018-02-21 | -$2.42M derived: sum of 3 quarters · filed 2018-02-21 | -$1.98M 10-K · filed 2018-02-21 | |
| 2015-09-30 | -$5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | -$981.00K derived: sum of 2 quarters · filed 2016-11-08 | -$544.00K 10-Q · filed 2016-11-08 | -$60.00K derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $4.78M 10-Q · filed 2016-08-09 | $5.26M derived: sum of 3 quarters · filed 2017-02-17 | $5.99M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $437.00K 10-Q · filed 2016-05-10 | $921.00K derived: sum of 2 quarters · filed 2017-02-17 | $1.65M derived: sum of 3 quarters · filed 2017-02-17 | $1.56M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $1.22M derived: sum of 2 quarters · filed 2017-02-17 | $1.12M derived: sum of 3 quarters · filed 2017-02-17 | $3.18M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $635.00K derived: sum of 2 quarters · filed 2015-11-10 | $2.69M 10-Q · filed 2015-11-10 | $1.24M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | -$98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.96M 10-Q · filed 2015-08-14 | $507.00K derived: sum of 3 quarters · filed 2016-02-26 | $1.31M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $2.06M 10-Q · filed 2015-05-12 | $605.00K derived: sum of 2 quarters · filed 2016-02-26 | $1.41M derived: sum of 3 quarters · filed 2016-02-26 | $956.00K derived: sum of 4 quarters · filed 2016-02-26 | $3.50M 10-Q · filed 2014-05-12 |
| 2013-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$649.00K derived: sum of 2 quarters · filed 2016-02-26 | -$1.10M derived: sum of 3 quarters · filed 2016-02-26 | $237.00K 10-K · filed 2016-02-26 | |
| 2013-09-30 | $804.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $351.00K derived: sum of 2 quarters · filed 2014-11-10 | $1.69M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | -$453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $886.00K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $1.34M 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $858.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |